{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T21:59:15Z","timestamp":1775167155163,"version":"3.50.1"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Erythropoiesis-stimulating agents (ESAs) are effective drugs to correct and maintain haemoglobin (Hb) levels, however, their use at doses to reach high Hb targets has been associated with an increased risk of cardiovascular adverse events, mortality and cancer. Presently used ESAs have a common mechanism of action but different pharmacokinetic and pharmacodynamic characteristics. Accordingly, the mode of activation of the erythropoietin (EPO) receptor can exert marked differences in downstream events. It is unknown whether the various ESA molecules have different efficacy\/safety profiles. The relative mortality and morbidity risks associated with the use of different types of ESAs remains poorly evaluated. Recently an observational study and a randomized clinical trial provided conflicting results regarding this matter. However, these two studies displayed several differences in patient characteristics and ESA molecules used. More importantly, by definition, randomized clinical trials avoid bias by indication and suffer less from confounding factors. Therefore they bring a higher degree of evidence. The scenario becomes even more complex when considering the new class of ESAs, called prolyl-hydroxylase domain (PHD) inhibitors. They are oral drugs that mimic exposure to hypoxia and stabilize hypoxia-inducible factor \u03b1. They profoundly differ from presently used ESAs, as they have multiple targets of action, including the stimulation of endogenous EPO synthesis, direct mobilization\/absorption of iron and a higher reduction of hepcidin. Accordingly, they have the potential to be more effective in inflamed patients with functional iron deficiency, i.e. the setting of patients who are at higher risk of cardiovascular events and mortality in response to present ESA use. As for ESAs, individual PHD inhibitors differ in molecular structure and degree of selectivity for the three main PHD isoforms; their efficacy and safety profiles may therefore be different from that of presently available ESAs.<\/jats:p>","DOI":"10.1093\/ndt\/gfaa034","type":"journal-article","created":{"date-parts":[[2020,2,4]],"date-time":"2020-02-04T20:09:20Z","timestamp":1580846960000},"page":"1369-1377","source":"Crossref","is-referenced-by-count":17,"title":["Are all erythropoiesis-stimulating agents created equal?"],"prefix":"10.1093","volume":"36","author":[{"given":"Francesco","family":"Locatelli","sequence":"first","affiliation":[{"name":"Past Director of the Department of Nephrology and Dialysis, Alessandro Manzoni Hospital, ASST Lecco, Lecco, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Vecchio","sequence":"additional","affiliation":[{"name":"Independent Researcher, Como, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[{"name":"Department of Scienze Mediche e Chirurgiche Avanzate, Division of Nephrology, University of Campania \u201cLuigi Vanvitelli\u201d, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5686-2089","authenticated-orcid":false,"given":"Roberto","family":"Minutolo","sequence":"additional","affiliation":[{"name":"Department of Scienze Mediche e Chirurgiche Avanzate, Division of Nephrology, University of Campania \u201cLuigi Vanvitelli\u201d, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"2021072609003212200_gfaa034-B1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0272-6386(12)80453-7","article-title":"Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis","volume":"19","author":"Martinez-Vea","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"2021072609003212200_gfaa034-B2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2009.09.019","article-title":"Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review","volume":"55","author":"Gandra","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2021072609003212200_gfaa034-B3","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1093\/ndt\/gfr697","article-title":"Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients","volume":"27","author":"Johansen","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2021072609003212200_gfaa034-B4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2215\/CJN.06020809","article-title":"Transfusion burden among patients with chronic kidney disease and anemia","volume":"5","author":"Lawler","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021072609003212200_gfaa034-B5","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"N Engl J Med"},{"key":"2021072609003212200_gfaa034-B6","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"355","author":"Dr\u00fceke","year":"2006","journal-title":"N Engl J Med"},{"key":"2021072609003212200_gfaa034-B7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"2021072609003212200_gfaa034-B8","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"2021072609003212200_gfaa034-B9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2007.06.008","article-title":"2007 update of hemoglobin target","volume":"50","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2021072609003212200_gfaa034-B10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease","volume":"153","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"2021072609003212200_gfaa034-B11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"2021072609003212200_gfaa034-B12","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"2021072609003212200_gfaa034-B13","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/bjc.2012.42","article-title":"Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer","volume":"106","author":"Aapro","year":"2012","journal-title":"Br J Cancer"},{"key":"2021072609003212200_gfaa034-B14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.7326\/M15-1839","article-title":"The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: a systematic review and meta-analysis","volume":"164","author":"Collister","year":"2016","journal-title":"Ann Intern Med"},{"key":"2021072609003212200_gfaa034-B15","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2021072609003212200_gfaa034-B16","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2021072609003212200_gfaa034-B17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1101\/gad.10.2.154","article-title":"Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis","volume":"10","author":"Lin","year":"1996","journal-title":"Genes Dev"},{"key":"2021072609003212200_gfaa034-B18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/bs.vh.2017.03.003","article-title":"Endogenous erythropoietin","volume":"105","author":"Korzeniewski","year":"2017","journal-title":"Vitam Horm"},{"key":"2021072609003212200_gfaa034-B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1084\/jem.20122760","article-title":"Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration","volume":"210","author":"Broxmeyer","year":"2013","journal-title":"J Exp Med"},{"key":"2021072609003212200_gfaa034-B20","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/j.1460-2075.1995.tb07192.x","article-title":"Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity","volume":"14","author":"Gouilleux","year":"1995","journal-title":"EMBO J"},{"key":"2021072609003212200_gfaa034-B21","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1126\/science.1184913","article-title":"Covering a broad dynamic range: information processing at the erythropoietin receptor","volume":"328","author":"Becker","year":"2010","journal-title":"Science"},{"key":"2021072609003212200_gfaa034-B22","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1182\/blood-2009-07-230870","article-title":"Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release","volume":"115","author":"Janmaat","year":"2010","journal-title":"Blood"},{"key":"2021072609003212200_gfaa034-B23","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1002\/jcp.22678","article-title":"\u03b2 Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase","volume":"226","author":"Su","year":"2011","journal-title":"J Cell Physiol"},{"key":"2021072609003212200_gfaa034-B24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/bdd.757","article-title":"Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep","volume":"32","author":"El-Komy","year":"2011","journal-title":"Biopharm Drug Dispos"},{"key":"2021072609003212200_gfaa034-B25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00277-013-1947-2","article-title":"Progress in detecting cell-surface protein receptors: the erythropoietin receptor example","volume":"93","author":"Elliott","year":"2014","journal-title":"Ann Hematol"},{"key":"2021072609003212200_gfaa034-B26","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molcel.2008.11.026","article-title":"Symmetric signaling by an asymmetric 1 erythropoietin: 2 erythropoietin receptor complex","volume":"33","author":"Zhang","year":"2009","journal-title":"Mol Cell"},{"key":"2021072609003212200_gfaa034-B27","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2310\/JIM.0b013e3181ed30bf","article-title":"Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?","volume":"59","author":"Hand","year":"2011","journal-title":"J Investig Med"},{"key":"2021072609003212200_gfaa034-B28","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/ndt\/gfx324","article-title":"Mechanisms and mediators of hypertension induced by erythropoietin and related molecules","volume":"33","author":"Agarwal","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2021072609003212200_gfaa034-B29","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/HYPERTENSIONAHA.107.090423","article-title":"Prevention of erythropoietin-associated hypertension","volume":"50","author":"Lee","year":"2007","journal-title":"Hypertension"},{"key":"2021072609003212200_gfaa034-B30","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/FJC.0b013e318040cf81","article-title":"Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action and mechanisms","volume":"49","author":"Baker","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"2021072609003212200_gfaa034-B31","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1136\/heartjnl-2011-300411","article-title":"Erythropoietin as a cardioprotective agent: down, but not out","volume":"97","author":"Opie","year":"2011","journal-title":"Heart"},{"key":"2021072609003212200_gfaa034-B32","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3390\/ijms14022258","article-title":"Regulation of erythropoietin receptor activity in endothelial cells by different erythropoietin (EPO) derivatives: an in vitro study","volume":"14","author":"Trincavelli","year":"2013","journal-title":"Int J Mol Sci"},{"key":"2021072609003212200_gfaa034-B33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.ajkd.2014.12.012","article-title":"Mortality risk of darbepoetin alfa versus epoetin alfa in patients with chronic kidney disease: systematic review and meta-analysis","volume":"66","author":"Wilhelm-Leen","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2021072609003212200_gfaa034-B34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5414\/CNP73094","article-title":"C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease","volume":"73","author":"Locatelli","year":"2010","journal-title":"Clin Nephrol"},{"key":"2021072609003212200_gfaa034-B35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1159\/000366478","article-title":"Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials","volume":"128","author":"Locatelli","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2021072609003212200_gfaa034-B36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s12325-016-0309-6","article-title":"Once-monthly continuous erythropoietin receptor activator (C.E.R.A.) in patients with hemodialysis-dependent chronic kidney disease: pooled data from phase III trials","volume":"33","author":"Locatelli","year":"2016","journal-title":"Adv Ther"},{"key":"2021072609003212200_gfaa034-B37","first-page":"CD010590","article-title":"Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2021072609003212200_gfaa034-B38","first-page":"CD009904","article-title":"Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease","volume":"8","author":"Saglimbene","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2021072609003212200_gfaa034-B39","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1681\/ASN.2018101007","article-title":"Types of erythropoietin-stimulating agents and mortality among patients undergoing hemodialysis","volume":"30","author":"Sakaguchi","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2021072609003212200_gfaa034-B40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/ndt\/gfm579","article-title":"Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha\/beta","volume":"23","author":"Bock","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2021072609003212200_gfaa034-B41","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2215\/CJN.01380219","article-title":"Cardiovascular safety and all-cause mortality of methoxy polyethylene glycol-epoetin beta and other erythropoiesis-stimulating agents in anemia of ckd: a randomized noninferiority trial","volume":"14","author":"Locatelli","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021072609003212200_gfaa034-B42","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0175-3","article-title":"Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?","volume":"74","author":"De Nicola","year":"2014","journal-title":"Drugs"},{"key":"2021072609003212200_gfaa034-B43","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021072609003212200_gfaa034-B44","article-title":"Are prolyl-hydroxylase inhibitors potential alternative treatments for anaemia in patients with chronic kidney disease?","author":"Locatelli","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2021072609003212200_gfaa034-B45","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2021072609003212200_gfaa034-B46","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2021072609003212200_gfaa034-B47","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2021072609003212200_gfaa034-B48","year":"2019"},{"key":"2021072609003212200_gfaa034-B49","author":"Provenzano","year":"2019"},{"key":"2021072609003212200_gfaa034-B50","author":"Fishbane","year":"2019"},{"key":"2021072609003212200_gfaa034-B51","author":"Provenzano","year":"2019"},{"key":"2021072609003212200_gfaa034-B52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.med.54.101601.152418","article-title":"Angiogenesis in ischemic and neoplastic disorders","volume":"54","author":"Semenza","year":"2003","journal-title":"Annu Rev Med"},{"key":"2021072609003212200_gfaa034-B53","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12931-019-1100-4","article-title":"Dysregulated expression of hypoxia-inducible factors augments myofibroblasts differentiation in idiopathic pulmonary fibrosis","volume":"20","author":"Aquino-G\u00e1lvez","year":"2019","journal-title":"Respir Res"},{"key":"2021072609003212200_gfaa034-B54","first-page":"37","article-title":"Time-dependent inhibition of PHD2","volume":"30","author":"Tcholakov","year":"2017","journal-title":"Biosci Rep"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/8\/1369\/39302044\/gfaa034.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/8\/1369\/39302044\/gfaa034.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T09:05:28Z","timestamp":1627290328000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/8\/1369\/5811114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":54,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,3,24]]},"published-print":{"date-parts":[[2021,7,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa034","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2020,3,24]]}}}